Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.

Wang YQ, Lv JW, Tang LL, Du XJ, Chen L, Li WF, Liu X, Guo Y, Lin AH, Mao YP, Sun Y, Chen YP, Ma J.

Oral Oncol. 2019 Mar;90:23-29. doi: 10.1016/j.oraloncology.2019.01.023. Epub 2019 Feb 1.

PMID:
30846172
2.

Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.

Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J, Sun Y.

Int J Cancer. 2019 Jan 6. doi: 10.1002/ijc.32099. [Epub ahead of print]

PMID:
30613964
3.

A multi-functional minimally-disruptive portable electrochemical system based on yeast/Co3O4/Au/SPEs for blood lead (II) measurement.

Nie J, He B, Zang YJ, Yin W, Han LR, Li WF, Hou CJ, Huo DQ, Yang M, Fa HB.

Bioelectrochemistry. 2019 Apr;126:156-162. doi: 10.1016/j.bioelechem.2018.12.008. Epub 2018 Dec 21.

PMID:
30597452
4.

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.

Zhang J, Peng H, Li WF, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

BMC Cancer. 2018 Dec 19;18(1):1276. doi: 10.1186/s12885-018-5177-9.

5.

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis.

Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J.

BMJ. 2018 Nov 8;363:k4226. doi: 10.1136/bmj.k4226.

6.

An evidence-based approach to assess the accuracy of intravoxel incoherent motion imaging for the grading of brain tumors.

Li WF, Niu C, Shakir TM, Chen T, Zhang M, Wang Z.

Medicine (Baltimore). 2018 Nov;97(45):e13217. doi: 10.1097/MD.0000000000013217. Review.

7.

10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.

Chen L, Zhang Y, Lai SZ, Li WF, Hu WH, Sun R, Liu LZ, Zhang F, Peng H, Du XJ, Lin AH, Sun Y, Ma J.

Oncologist. 2019 Jan;24(1):e38-e45. doi: 10.1634/theoncologist.2017-0577. Epub 2018 Aug 6.

PMID:
30082487
8.

The current status of clinical trials focusing on nasopharyngeal carcinoma: A comprehensive analysis of ClinicalTrials.gov database.

Peng H, Chen L, Chen YP, Li WF, Tang LL, Lin AH, Sun Y, Ma J.

PLoS One. 2018 May 2;13(5):e0196730. doi: 10.1371/journal.pone.0196730. eCollection 2018.

9.

Prognostic value of nutritional risk screening 2002 scale in nasopharyngeal carcinoma: A large-scale cohort study.

Peng H, Chen BB, Tang LL, Chen L, Li WF, Zhang Y, Mao YP, Sun Y, Liu LZ, Tian L, Guo Y, Ma J.

Cancer Sci. 2018 Jun;109(6):1909-1919. doi: 10.1111/cas.13603. Epub 2018 May 18.

10.

Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.

Peng H, Tang LL, Chen BB, Chen L, Li WF, Mao YP, Liu X, Zhang Y, Liu LZ, Tian L, Guo Y, Sun Y, Ma J.

Oral Oncol. 2018 Apr;79:40-46. doi: 10.1016/j.oraloncology.2018.02.011. Epub 2018 Feb 16.

PMID:
29598949
11.

Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.

Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Guo Y, Sun Y, Ma J.

BMC Cancer. 2018 Mar 27;18(1):323. doi: 10.1186/s12885-018-4268-y.

12.

Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.

Peng H, Tang LL, Liu X, Chen L, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Guo Y, Sun Y, Ma J.

Cancer Sci. 2018 May;109(5):1609-1616. doi: 10.1111/cas.13589. Epub 2018 Apr 19.

13.

Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.

Xu C, Sun R, Tang LL, Chen L, Li WF, Mao YP, Zhou GQ, Guo R, Lin AH, Sun Y, Ma J, Hu WH.

Oral Oncol. 2018 Mar;78:37-45. doi: 10.1016/j.oraloncology.2018.01.008. Epub 2018 Feb 20.

PMID:
29496056
14.

Induction Chemotherapy plus Concurrent Chemoradiotherapy in Endemic Nasopharyngeal Carcinoma: Individual Patient Data Pooled Analysis of Four Randomized Trials.

Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY, Ma J.

Clin Cancer Res. 2018 Apr 15;24(8):1824-1833. doi: 10.1158/1078-0432.CCR-17-2656. Epub 2018 Feb 5.

PMID:
29431618
15.

Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy.

Lv JW, Qi ZY, Zhou GQ, He XJ, Chen YP, Mao YP, Chen L, Tang LL, Li WF, Lin AH, Ma J, Sun Y.

Cancer Sci. 2018 Mar;109(3):751-763. doi: 10.1111/cas.13474. Epub 2018 Jan 31.

16.

Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Analysis of a multicenter, phase III randomized trial.

Zhang Y, Li WF, Liu X, Chen L, Sun R, Sun Y, Liu Q, Ma J.

Radiother Oncol. 2018 Oct;129(1):18-22. doi: 10.1016/j.radonc.2017.12.002. Epub 2017 Dec 16.

PMID:
29258695
17.

Significant value of 18F-FDG-PET/CT in diagnosing small cervical lymph node metastases in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Peng H, Chen L, Tang LL, Li WF, Mao YP, Guo R, Zhang Y, Liu LZ, Tian L, Zhang X, Lin XP, Guo Y, Sun Y, Ma J.

Chin J Cancer. 2017 Dec 19;36(1):95. doi: 10.1186/s40880-017-0265-9.

18.

A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy.

Peng H, Chen BB, Chen L, Chen YP, Liu X, Tang LL, Mao YP, Li WF, Zhang Y, Lin AH, Sun Y, Ma J.

Oral Oncol. 2017 Dec;75:89-94. doi: 10.1016/j.oraloncology.2017.11.001. Epub 2017 Nov 8.

PMID:
29224830
19.

Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma.

Li WF, Zhang Y, Liu X, Tang LL, Tian L, Guo R, Liu LZ, Sun Y, Ma J.

Oral Oncol. 2017 Dec;75:120-126. doi: 10.1016/j.oraloncology.2017.10.020. Epub 2017 Nov 10.

PMID:
29224808
20.

Proposal of a Pretreatment Nomogram for Predicting Local Recurrence after Intensity-Modulated Radiation Therapy in T4 Nasopharyngeal Carcinoma: A Retrospective Review of 415 Chinese Patients.

Zhang LL, Li YY, Hu J, Zhou GQ, Chen L, Li WF, Lin AH, Ma J, Qi ZY, Sun Y.

Cancer Res Treat. 2018 Oct;50(4):1084-1095. doi: 10.4143/crt.2017.359. Epub 2017 Nov 15.

21.

Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.

Li WF, Zhang Y, Huang XB, Du XJ, Tang LL, Chen L, Peng H, Guo R, Sun Y, Ma J.

Chin J Cancer. 2017 Nov 7;36(1):87. doi: 10.1186/s40880-017-0256-x.

22.

Decreased Overall and Cancer-Specific Mortality with Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Treated by Intensity-modulated Radiotherapy: Multivariate Competing Risk Analysis.

Zhang J, Peng H, Chen L, Li WF, Mao YP, Liu LZ, Tian L, Guo Y, Sun Y, Ma J.

J Cancer. 2017 Aug 3;8(13):2587-2594. doi: 10.7150/jca.20081. eCollection 2017.

23.

Neutropenia during the First Cycle of Induction Chemotherapy Is Prognostic for Poor Survival in Locoregionally Advanced Nasopharyngeal Carcinoma: A Real-World Study in an Endemic Area.

Xu C, Yang SP, Zhang Y, Tang LL, Zhou GQ, Liu X, Mao YP, Guo R, Li WF, Chen L, Lin AH, Sun Y, Ma J.

Cancer Res Treat. 2018 Jul;50(3):777-790. doi: 10.4143/crt.2017.255. Epub 2017 Jul 24.

24.

Refining the Role of Lymph Node Biopsy in Survival for Patients with Nasopharyngeal Carcinoma: Population-Based Study from the Surveillance Epidemiology and End-Results Registry.

Lv JW, Zhou GQ, Chen YP, Tang LL, Mao YP, Chen L, Li WF, Lin AH, Ma J, Sun Y.

Ann Surg Oncol. 2017 Sep;24(9):2580-2587. doi: 10.1245/s10434-017-5966-4. Epub 2017 Jul 5.

PMID:
28681157
25.

Optimal Modality for Detecting Distant Metastasis in Primary Nasopharyngeal Carcinoma during Initial Staging: A Systemic Review and Meta-analysis of 1774 Patients.

Xu C, Zhang Y, Peng L, Liu X, Li WF, Sun Y, Zhang X, Lin XP, Liu Q, Ma J.

J Cancer. 2017 Apr 10;8(7):1238-1248. doi: 10.7150/jca.18361. eCollection 2017.

26.

Reporting Quality of Randomized, Controlled Trials Evaluating Combined Chemoradiotherapy in Nasopharyngeal Carcinoma.

Chen YP, Chen L, Li WF, Lee AWM, Vermorken JB, Wee J, O'Sullivan B, Eisbruch A, Lin JC, Mai HQ, Zhang L, Guo Y, Lin AH, Sun Y, Ma J.

Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):170-176. doi: 10.1016/j.ijrobp.2017.01.214. Epub 2017 Jan 29. Review.

PMID:
28586958
27.

Establishing and applying nomograms based on the 8th edition of the UICC/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy.

Xu C, Chen YP, Liu X, Li WF, Chen L, Mao YP, Zhang Y, Guo R, Zhou GQ, Tang LL, Lin AH, Sun Y, Ma J.

Oral Oncol. 2017 Jun;69:99-107. doi: 10.1016/j.oraloncology.2017.04.015. Epub 2017 May 2.

PMID:
28559028
28.

The feasibility of contralateral lower neck sparing intensity modulation radiated therapy for nasopharyngeal carcinoma patients with unilateral cervical lymph node involvement.

Tang LL, Tang XR, Li WF, Chen L, Tian L, Lin AH, Sun Y, Ma J.

Oral Oncol. 2017 Jun;69:68-73. doi: 10.1016/j.oraloncology.2017.03.010. Epub 2017 Apr 17.

PMID:
28559023
29.

Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.

Lv JW, Chen YP, Huang XD, Zhou GQ, Chen L, Li WF, Tang LL, Mao YP, Guo Y, Xu RH, Ma J, Sun Y.

Cancer. 2017 Sep 15;123(18):3540-3549. doi: 10.1002/cncr.30775. Epub 2017 May 10.

30.

A National Study of Survival Trends and Conditional Survival in Nasopharyngeal Carcinoma: Analysis of the National Population-Based Surveillance Epidemiology and End Results Registry.

Lv JW, Huang XD, Chen YP, Zhou GQ, Tang LL, Mao YP, Li WF, Lin AH, Ma J, Sun Y.

Cancer Res Treat. 2018 Apr;50(2):324-334. doi: 10.4143/crt.2016.544. Epub 2017 Apr 19.

31.

Socioeconomic factors and survival in patients with non-metastatic head and neck squamous cell carcinoma.

Xu C, Chen YP, Liu X, Tang LL, Chen L, Mao YP, Zhang Y, Guo R, Zhou GQ, Li WF, Lin AH, Sun Y, Ma J.

Cancer Sci. 2017 Jun;108(6):1253-1262. doi: 10.1111/cas.13250. Epub 2017 May 20.

32.

Clinical treatment considerations in the intensity-modulated radiotherapy era for patients with N0-category nasopharyngeal carcinoma and enlarged neck lymph nodes.

Peng H, Chen L, Guo R, Zhang Y, Li WF, Mao YP, Sun Y, Zhang F, Liu LZ, Tian L, Ma J.

Chin J Cancer. 2017 Mar 24;36(1):32. doi: 10.1186/s40880-017-0199-2.

33.

Critical Evaluation of the Quality and Recommendations of Clinical Practice Guidelines for Nasopharyngeal Carcinoma.

Chen YP, Wang YQ, Li WF, Chen L, Xu C, Lu TX, Lin AH, Yao JJ, Li YC, Sun Y, Mao YP, Ma J.

J Natl Compr Canc Netw. 2017 Mar;15(3):336-344.

PMID:
28275034
34.

Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up.

Liu X, Tang LL, Du XJ, Li WF, Chen L, Zhou GQ, Guo R, Liu Q, Sun Y, Ma J.

J Cancer. 2017 Feb 10;8(3):455-459. doi: 10.7150/jca.17104. eCollection 2017.

35.

Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy.

Peng H, Chen L, Zhang J, Li WF, Mao YP, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

J Cancer. 2017 Feb 10;8(3):371-377. doi: 10.7150/jca.16732. eCollection 2017.

36.

Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: A secondary analysis of a randomized phase 3 clinical trial.

Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, Guo Y, Sun Y, Ma J.

Cancer. 2017 May 1;123(9):1643-1652. doi: 10.1002/cncr.30520. Epub 2016 Dec 21.

37.

Use of pretreatment serum uric acid level to predict metastasis in locally advanced nasopharyngeal carcinoma.

Du XJ, Chen L, Li WF, Tang LL, Mao YP, Guo R, Sun Y, Lin AH, Ma J.

Head Neck. 2017 Mar;39(3):492-497. doi: 10.1002/hed.24631. Epub 2016 Dec 20.

PMID:
27997061
38.

Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference.

Liu X, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J.

JAMA Oncol. 2017 Mar 1;3(3):414-416. doi: 10.1001/jamaoncol.2016.4899. No abstract available.

PMID:
27893034
39.

Optimize the cycle of neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: A propensity score matching analysis.

Peng H, Chen L, Li WF, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

Oral Oncol. 2016 Nov;62:78-84. doi: 10.1016/j.oraloncology.2016.10.014. Epub 2016 Oct 19.

PMID:
27865375
40.

Induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Li WF, Chen L, Sun Y, Ma J.

Chin J Cancer. 2016 Nov 15;35(1):94.

41.

Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.

Peng H, Chen L, Li WF, Zhang Y, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

PLoS One. 2016 Nov 11;11(11):e0166194. doi: 10.1371/journal.pone.0166194. eCollection 2016.

42.

Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.

Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J.

Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.

PMID:
27686945
43.

Publication status of contemporary oncology randomised controlled trials worldwide.

Chen YP, Liu X, Lv JW, Li WF, Zhang Y, Guo Y, Lin AH, Sun Y, Mao YP, Ma J.

Eur J Cancer. 2016 Oct;66:17-25. doi: 10.1016/j.ejca.2016.06.010. Epub 2016 Aug 11.

PMID:
27522246
44.

Prognostic Value of the Cumulative Cisplatin Dose During Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Secondary Analysis of a Prospective Phase III Clinical Trial.

Peng H, Chen L, Zhang Y, Li WF, Mao YP, Zhang F, Guo R, Liu LZ, Lin AH, Sun Y, Ma J.

Oncologist. 2016 Nov;21(11):1369-1376. doi: 10.1634/theoncologist.2016-0105. Epub 2016 Aug 5.

45.

Prognostic Value of Neoadjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma with Low Pre-treatment Epstein-Barr Virus DNA: a Propensity-matched Analysis.

Peng H, Chen L, Li WF, Guo R, Zhang Y, Zhang F, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

J Cancer. 2016 Jul 5;7(11):1465-71. doi: 10.7150/jca.15736. eCollection 2016.

46.

Exploration and Validation of C-Reactive Protein/Albumin Ratio as a Novel Inflammation-Based Prognostic Marker in Nasopharyngeal Carcinoma.

Zhang Y, Zhou GQ, Liu X, Chen L, Li WF, Tang LL, Liu Q, Sun Y, Ma J.

J Cancer. 2016 Jul 4;7(11):1406-12. doi: 10.7150/jca.15401. eCollection 2016.

47.

Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 Cases.

Zhang Y, Peng H, Guo R, Li WF, Chen L, Liu X, Tang LL, Liu LZ, Li L, Liu Q, Sun Y, Ma J.

J Cancer. 2016 Jun 28;7(10):1353-9. doi: 10.7150/jca.15141. eCollection 2016.

48.

The Tumour Response to Induction Chemotherapy has Prognostic Value for Long-Term Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma.

Peng H, Chen L, Zhang Y, Li WF, Mao YP, Liu X, Zhang F, Guo R, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

Sci Rep. 2016 Apr 21;6:24835. doi: 10.1038/srep24835.

49.

The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy.

Peng H, Chen L, Li WF, Guo R, Mao YP, Zhang Y, Zhang F, Liu LZ, Tian L, Lin AH, Sun Y, Ma J.

Sci Rep. 2016 Apr 13;6:24332. doi: 10.1038/srep24332.

50.

Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.

Peng H, Chen L, Zhang Y, Guo R, Li WF, Mao YP, Tan LL, Sun Y, Zhang F, Liu LZ, Tian L, Lin AH, Ma J.

Oncotarget. 2016 Apr 26;7(17):24208-16. doi: 10.18632/oncotarget.8144.

Supplemental Content

Loading ...
Support Center